# BeiCell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beicell

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.beicelltherapeutics.com
- Total disclosed funding: $14M
- Latest round: Series A (Dec 29, 2025)
- Investors on record: 6

## About

Founded in 2022 and based in Beijing, China, Beijing Beiqi Biomedicine Co., Ltd. doing business as BeiCell, operates as a bitechnology company that engages in the development of small molecule drug that provides off-the-shelf cell therapy products. In December 2025, BeiCell closed Series A+ funding from new investors Sanqi Interactive Entertainment Venture Capital, Zhouji Tongli Capital, with participation from returning investor Yanyuan Chuangtou.

The company specializes in the development of cell therapy drugs based on the chemically induced pluripotent stem cell (CiPSC) technology platform. This platform reprograms human somatic cells into pluripotent stem cells that exhibit key characteristics of embryonic stem cells, providing significant advantages over traditional methods, such as safety, simplicity, and efficiency. The primary service involves extracting immune cells from healthy donors utilizing various sources, including peripheral blood and cord blood, which are then engineered, expanded, and administered to patients as allogeneic or 'off-the-shelf' immunotherapy. Targeted end-use cases for these therapies include treatment options for various diseases, enhancing patient outcomes in immunotherapy.

BeiCell's revenue structure is centered around B2B transactions, wherein the company collaborates with healthcare institutions and research organizations to provide advanced cell therapy solutions.

## Funding rounds

- Series A, Dec 29, 2025 — Zhouji Tongli Capital, Sanqi Interactive Entertainment Venture Capital, Yanyuan Chuangtou
- Series A, Dec 11, 2024, $14M — Green Pine Capital Partners, NNFE, Beijing Capital Science and Technology Development Group Investment Management, Yanyuan Chuangtou

## Investors

- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A
- NNFE (https://capitalatlas.ai/funds/nnfe) — Series A
- Beijing Capital Science and Technology Development Group Investment Management (https://capitalatlas.ai/funds/beijing-capital-science-and-technology-development-group-inv) — Series A
- Yanyuan Chuangtou (https://capitalatlas.ai/funds/yanyuan-chuangtou) — Series A
- Zhouji Tongli Capital (https://capitalatlas.ai/funds/zhouji-tongli-capital) — Series A
- Sanqi Interactive Entertainment Venture Capital (https://capitalatlas.ai/funds/sanqi-interactive-entertainment-venture-capital) — Series A